US20020037583A1 - Methods for protein transfer - Google Patents
Methods for protein transfer Download PDFInfo
- Publication number
- US20020037583A1 US20020037583A1 US09/957,056 US95705601A US2002037583A1 US 20020037583 A1 US20020037583 A1 US 20020037583A1 US 95705601 A US95705601 A US 95705601A US 2002037583 A1 US2002037583 A1 US 2002037583A1
- Authority
- US
- United States
- Prior art keywords
- protein
- cells
- domain
- cell
- lipidated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 202
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 200
- 238000000034 method Methods 0.000 title claims abstract description 106
- 238000012546 transfer Methods 0.000 title abstract description 32
- 210000004027 cell Anatomy 0.000 claims abstract description 205
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 56
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 56
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 26
- 229940022399 cancer vaccine Drugs 0.000 claims abstract description 21
- 238000009566 cancer vaccine Methods 0.000 claims abstract description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 15
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 201000011510 cancer Diseases 0.000 claims abstract description 10
- 230000011664 signaling Effects 0.000 claims abstract description 10
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 28
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims description 13
- 229960005486 vaccine Drugs 0.000 claims description 13
- 102000004127 Cytokines Human genes 0.000 claims description 12
- 108090000695 Cytokines Proteins 0.000 claims description 12
- 238000001727 in vivo Methods 0.000 claims description 12
- 230000006052 T cell proliferation Effects 0.000 claims description 11
- 239000011248 coating agent Substances 0.000 claims description 11
- 238000000576 coating method Methods 0.000 claims description 11
- 230000004957 immunoregulator effect Effects 0.000 claims description 11
- 238000000338 in vitro Methods 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 9
- 102100032937 CD40 ligand Human genes 0.000 claims description 8
- 108010052285 Membrane Proteins Proteins 0.000 claims description 8
- 108010029697 CD40 Ligand Proteins 0.000 claims description 7
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 6
- 102000018697 Membrane Proteins Human genes 0.000 claims description 6
- 230000000735 allogeneic effect Effects 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 5
- 108010017987 CD30 Ligand Proteins 0.000 claims description 4
- 102100036008 CD48 antigen Human genes 0.000 claims description 4
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 108010084313 CD58 Antigens Proteins 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 3
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 claims description 3
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 3
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 claims description 3
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 claims description 3
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 claims description 3
- 101000884281 Rattus norvegicus Signal transducer CD24 Proteins 0.000 claims description 3
- 101710120037 Toxin CcdB Proteins 0.000 claims description 3
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 230000028327 secretion Effects 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 2
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 claims 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims 2
- 230000027455 binding Effects 0.000 abstract description 6
- 210000000170 cell membrane Anatomy 0.000 abstract description 5
- 230000006870 function Effects 0.000 description 13
- 210000004881 tumor cell Anatomy 0.000 description 12
- 108010039471 Fas Ligand Protein Proteins 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 102100037850 Interferon gamma Human genes 0.000 description 9
- 108010074328 Interferon-gamma Proteins 0.000 description 9
- 108010002350 Interleukin-2 Proteins 0.000 description 9
- 210000000612 antigen-presenting cell Anatomy 0.000 description 9
- 230000000139 costimulatory effect Effects 0.000 description 9
- 229940030156 cell vaccine Drugs 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 108091006020 Fc-tagged proteins Proteins 0.000 description 7
- 230000028993 immune response Effects 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 238000001516 cell proliferation assay Methods 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- 230000004940 costimulation Effects 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 102000002627 4-1BB Ligand Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000006276 transfer reaction Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108010031480 Artificial Receptors Proteins 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 102000004634 CD30 Ligand Human genes 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 2
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 2
- 229940097277 hygromycin b Drugs 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 1
- 0 *C[C@]([N+]([O-])=O)IC(*)* Chemical compound *C[C@]([N+]([O-])=O)IC(*)* 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100026398 Cyclic AMP-responsive element-binding protein 3 Human genes 0.000 description 1
- 238000011767 DBA/2J (JAX™ mouse strain) Methods 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 1
- 101000855520 Homo sapiens Cyclic AMP-responsive element-binding protein 3 Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 241000396377 Tranes Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000009133 cooperative interaction Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000011293 immunotherapeutic strategy Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000012803 optimization experiment Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 238000007591 painting process Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000004492 positive regulation of T cell proliferation Effects 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0006—Modification of the membrane of cells, e.g. cell decoration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/58—Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
Definitions
- the present invention relates to novel methods for transferring one or more proteins to a cell.
- the methodology is useful in the treatment of cancer and autoimmune diseases, and for determining costimulator activation thresholds and cooperative interactions among costimulators.
- T-cells including cytotoxic T-lymphocytes (CTLs) are a critical component of effective human immune responses to tumors, viral infections and other infectious diseases.
- T-cells destroy neoplastic or virally infected cells through recognition of antigenic peptides presented by MHC class I molecules on the surfaces of target cells.
- Activation of T-cells is dependent upon coordinate signaling through antigen receptors and costimulator receptors on T-cell surfaces. Many mechanisms contribute to the escape of tumor cells and virally infected cells from immune surveillance. One of the mechanisms is that these cells lack the costimulatory molecules required for T-cell activation.
- Immunotherapeutic strategies have been developed that are predicated upon expressing costimulators on tumor cell, and other antigen-presenting cell, surfaces.
- APCs Professional antigen-presenting cells
- APCs can be converted into deletional APCs, or “artificial veto cells”, by expressing coinhibitors at their surfaces. This is discussed, for example, in U.S. Pat. Nos. 5,242,687; 5,601,828; and 5,623,056. Such coinhibitors bind to coinhibitor receptors on cells, leading to T-cell inactivation.
- APCs such as tumor cells
- costimulators and coinhibitors on APCs such as tumor cells
- APCs When used for APC and tumor cell engineering, gene transfer techniques have shortcomings. For example, APCs, including tumor cells, are often poorly transfectable. In addition, transfection proceedings are cumbersome and time-consuming. Furthermore, expressing more than a costimulator (or coinhibitor) is difficult. These and other issues have impeded the widespread application of gene therapy for APC and tumor cell engineering.
- Protein transfer offers a number of advantages over gene transfer for engineering APCs and other cells. These advantages include the ability to modify poorly transfectable cells (for example, biopsy-derived tumor cells), the simplicity of expressing multiple proteins on the same cell surface, and the relative ease and rapidity of the procedure.
- poorly transfectable cells for example, biopsy-derived tumor cells
- MHC protein derivatives for protein transfer has been reported.
- a shortcoming of the GPI protein transfer strategy resides in scaling up the purification of GPI proteins from membranes of transfected cells.
- the present invention has met the above needs, by providing methods for quantitative transfer of a domain having trans-signaling and/or adhesion function onto a cell surface.
- the domain will be the extracellular domain having one or both of these functions.
- the extracellular domain of an immuno-regulatory molecule is used.
- the present methods provide a two-step protein transfer approach, which permits delivery of graded amounts of proteins to a cell surface.
- the methods utilize a fusion protein comprised of at least two domains, one of which preferably encodes a molecule having immunoregulatory function. By adding the fusion protein to cells coated with a lipidated protein, fine titration of, for example, the immunoregulatory molecule's extracellular domain is achieved.
- the present protein transfer methods have wide application.
- the methods have been used to establish that costimulator thresholds exist, and that the levels of surface costimulator on APCs can dictate both the magnitude and the quality of evoked T-cell responses.
- the present methods are also applicable to the generation of cancer vaccines; these vaccines show significant anti-tumor effects in vivo.
- the methods can be used to generate artificial veto cells, expressing one or more coinhibitors, that can be used to delete pathogenic T-cells. Cells produced according to the present methods are therefore useful in the treatment of cancer and also in the treatment of autoimmune diseases.
- the methodologies described herein can also be used in the establishment of animal models and for the study of immunological issues regarding, for example, T-cell activation, use of costimulators to override apoptotic signals, function of coinhibitors versus costimulators, synergy of costimulators used in the treatment of cancer, and use of coinhibitors in the treatment of autoimmune diseases.
- FIG. 1, including 1 A, 1 B and 1 C, demonstrates the efficacy of coating cells with a lipidated protein, according to the methods of Example 1.
- FIG. 2 provides the SDS-PAGE analysis of recombinant B7-1 ⁇ Fc ⁇ 1 prepared as described in Example 1.
- FIG. 3 demonstrates that the present methods achieve fusion protein transfer (FIG. 3A), in a quantitative manner (FIG. 3B), as described in Example 1.
- FIG. 4 demonstrates the stimulation of T-cell proliferation in the presence of various proteins (as indicated) using either PHA (FIG. 4A) or anti-CD3 mAb (FIG. 4B) as a first signal, as described in Example 1.
- FIG. 5 demonstrates B7-1 threshold concentrations for T-cell proliferation using either PHA (FIG. 5A) or anti-CD3 mAb (FIG. 5B) as a first signal, as described in Example 1.
- FIG. 6 provides a comparison of B7 concentration thresholds for IFN- ⁇ versus IL-2 production using either PHA (FIG. 6A) or anti-CD3 mAb (FIG. 6B) as a first signal, as described in Example 1.
- FIG. 7 provides comparative single-cell analyses of B7-1 concentration thresholds for IFN- ⁇ versus IL-2, as described in Example 1.
- FIG. 8 shows the effect of reaction temperature during protein transfer on the stability of transferred protein, as described in Example 2.
- FIG. 9 demonstrates the efficacy of the present cancer vaccines in protecting a patient against a post-immunization tumor challenge, as described in Example 3.
- FIG. 10 demonstrates the efficacy of the present cancer vaccines in treating a pre-existing tumor, as described in Example 4.
- FIG. 11 demonstrates the efficacy of the present cancer vaccines by intratumoral injection of costimulators, as described in Example 5.
- FIG. 12 shows the results of the JAM assay, as described in Example 6.
- the present invention is directed to methods for transferring one or more proteins to a cell, generally comprising the steps of coating the surface of a cell with a first protein, which is a lipidated protein, and contacting the coated cell with a second protein, which is a fusion protein.
- the fusion protein is comprised of a first domain having affinity for the lipidated protein and a second domain of a peptide, protein, or derivative or fragment thereof, having trans signaling and/or adhesion function.
- the extracellular domain is used, and the second domain has immunoregulatory function.
- “Derivative”, as used in reference to peptides and proteins, refers to variants of peptides and proteins such as analogues wherein, for example, one or more amino acids within the peptide chain has been deleted, added or replaced with an alternative amino acid.
- a “fragment” refers to a portion of the amino acid sequence of a peptide or protein. It will be understood that “derivatives” and “fragments” of peptides and proteins retain the physiological function of the wild type peptide or protein and thus are biologically active.
- the present methods are applicable to any cell having a lipid bilayer membrane.
- any kind of a patient's autologous cells can be used, harvested by any means known in the art.
- Use of any allogeneic mammalian cell line is also within the scope of the present invention.
- allogeneic cell lines suitable for use in the present invention include, but are not limited to, EL-4 cells (mouse thymoma cells), 293 cells (human kidney cells), K562 cells (human leukemia cells), Daudi cells (human B cell line) and JY cells (human B cell line). These cells are commercially available from the American Type Culture Collection, Manassas, VA. Non-commercially available cell lines are also within the scope of the present invention.
- Any protein that can be lipidated is suitable for use in the present methods. Examples include, but are not limited to, protein A and protein G, both of which are commercially available. Similarly, any lipid can be used to prepare the lipidated protein. Lipids having carbon chains between about 12 and 22 are preferred, with a carbon chain of 16 (palmitate) being most preferred. The length of the lipid chain can be varied based upon the needs and desires of the user. It will be understood to those skilled in the art that the lipidated portion of the first protein will become attached to or incorporated into the phospholipid bilayer that makes up the membrane of the cell, and that this is what is meant by the phrase “coating the surface of the cell” as that phrase is used herein.
- the amount of lipidated protein used to coat the cell may also vary based on the needs and desires of the user, and based on the particular lipid and particular protein selected Preferably, enough lipidated protein is used to coat the entire cell. This amount will typically be at least about 30 micrograms of lipidated protein for every 5 ⁇ 10 6 cells.
- the second protein is a fusion protein in which two different domains have been fused, such as through recombinant DNA technology standardly used in the art, to create a single DNA sequence.
- the first domain can be attached at either the amino terminus or the carboxyl terminus of the fusion protein.
- the first domain encodes a peptide, protein, or derivative or fragment thereof, what has affinity for the lipidated protein.
- the protein used in the lipidated protein is ideally selected in conjunction with the protein encoded by the first domain of the fusion protein, so that proteins having affinity for one another are used. Affinity between the proteins can be determined by Biacore technology or other methods familiar in the art.
- the fusion protein binds to the lipidated protein, which has already been incorporated into the cell membrane. In this manner, the fusion protein is transferred to the cell.
- a particularly preferred combination uses a palmitated protein A and a first domain encoding an Fc region.
- the Fc region of human immunoglobulin G1 (IgG1) designated Fc ⁇ 1
- Fc ⁇ 1 can be used.
- Other suitable first domains in the fusion protein include leucine zipper protein domains and single-chain Fv derivative domains.
- the second domain of the fusion protein encodes a peptide, protein, or derivative or fragment thereof, having immunoregulatory function and capable of tranes signaling to a second cell.
- Examples include, but are not limited to, costimulators and coinhibitors. Any suitable costimulator can be used including but not limited to B7-1, B7-2, CD48, ICAM-1, ICAM-2, ICAM-3, LFA-3, CD30 Ligand (CD30L), CD40 Ligand (CD40L), 4-IBB Ligand (4-1BBL), and heat stable antigen.
- any suitable coinhibitor can be used including, but not limited to, CD8, FasL and PP14.
- the fusion protein of the present invention can be either a type I or type II protein. Methods for transferring a type II protein to a cell have never been reported. Because the methods of the present invention are equally applicable to type I and type II proteins, they provide a significant advance over the art. Examples of type I membrane proteins include B7-1, B7-2 and CD48; examples of type II membrane proteins include Fas ligand (FasL or CD95L), CD40L, and 4-1BBL. For the type II proteins, the first domains are fused at the carboxyl termini of the type II proteins in order to preserve the functional ends of the molecules. These lists are not exhaustive of the costimulators, coinhibitors and other proteins that can be transferred according to the present invention; the lists reflect all forms of the various molecules including, but not limited to, human and murine forms.
- the present methods are capable of eliciting an immune response by binding to, and trans signaling through a counter-receptor on a second cell.
- more than one fusion protein can be used to coat a single cell.
- two, three, four, or more trans signaling for example, immunoregulatory proteins
- trans signaling for example, immunoregulatory proteins
- combinations of such proteins can be chosen to have the greatest immunological effect; combinations having additive or even synergistic benefits can be selected and used according to the present methods.
- the present methods are further unique in that proteins can be delivered to a cell's surface in a quantitative manner. As noted above, it is preferred to use enough lipidated protein to fully coat the cell. The amount of fusion protein that becomes transferred to the cell is therefore determined by the amount of fusion protein used to contact the coated cell; thus the amount of fusion protein is the limiting or determinative factor. When using more than one fusion protein, predetermined ratios of fusion proteins can be used to contact the coated cell; protein will be transferred to the cell in these approximate ratios.
- the present methods can be effected either in vivo or in vitro.
- the lipidated protein and the fusion protein are injected directly into a patient.
- the injection can occur sequentially (with the lipidated protein first) or concurrently, with premixing of the lipidated protein and the fusion protein(s).
- Injection can be localized, for example, intra-tumoral, or systemic, for example, into a vessel.
- the present methods, and cells produced thereby in contrast to other art-reported methods, have particularly high protein stability, making the present method practical for in vivo application.
- In vitro methods involve the extraction of cells from a patient, and the subsequent coating and contacting of the cells; alternatively, commercially obtained allogeneic cells can be used. In either case, the treated cells can then be injected into a patient.
- the present invention is further directed to methods for determining costimulator activation thresholds in T-cells. These methods generally comprise transferring one or more fusion proteins to a cell, in the manner described above. The cells to which protein has been transferred are then mixed with T-cells. T-cells can be, for example, harvested from peripheral blood mononuclear cells by methods known in the art. T-cell proliferation, if any, can be measured, as can cytokine secretion levels according to means known in the art, such as those described in the Example section.
- the present invention is further directed to methods for treating an illness using the present protein transfer technology.
- These methods generally comprise administering to a patient an effective amount of the cells prepared in vitro according to the method described above, or administering the proteins in vivo.
- the method can be performed by either in vivo or in vitro protein transfer of the fusion protein(s) to the target cells.
- in vitro methods either extracted autologous cells or allogeneic cells are coated with a lipidated protein and contacted with one or more fusion proteins. An effective amount of these cells are then administered to a patient.
- lipidated protein and one or more fusion proteins are administered to a patient in an amount sufficient to result in transfer of an effective amount of fusion protein(s) to an effective amount of cells.
- Illness refers to cancer and autoimmune and alloimmune diseases, including but not limited to arthritis, rheumatoid arthritis, asthma, graft-versus-host disease, organ rejection, systemic lupus erythematosis, atopic allergy, inflammatory bowel disease, multiple sclerosis and allergic dermatitis.
- the methods are particularly applicable to treatment of cancer, in that the lipidated protein and fusion protein(s) in the in vivo methodology, or the coated and contacted cells in the in vitro methodology, can be directly injected into one or more tumors of the patient.
- “Patient” is used herein to refer to members of the animal kingdom, including humans. The present methods are generally applicable to patients capable of generating at least a minimal immune response.
- an effective amount of cells produced by the present protein transfer methods should be used in the present treatment methods.
- the effective amount is that amount of cells that will deliver the amount of protein to a patient needed to bring about a desired result
- the desired result can be, for example, stimulation of an immune response or suppression of an immune response.
- an effective amount would be that amount which would protect a patient against tumor growth or reduction, if not elimination, of tumors.
- an effective amount would be that amount which would alleviate if not eliminate one or more symptoms of the autoimmune or alloimmune disease being treated.
- the effective amount will vary from patient to patient depending on such factors as the patient's size, the condition of the patient's immune system, the patient's ability to mount an immune response, and the type and severity of the illness.
- the appropriate effective amount for each patient can be determined by one skilled in the art, and will generally be at least about 10 7 modified cells or 100 ⁇ g Fc fusion protein intratumorally.
- the present invention is further directed to a cancer vaccine comprising cells prepared according to the present protein transfer methods contained in a suitable carrier.
- a suitable carrier can be used, provided compatibility problems do not arise. Examples include PBS, and serum-free medium.
- the vaccine can include a variety of fusion proteins; different cells each having a different fusion protein, or cells having more than one fusion protein attached thereto, can be used for example.
- a “cocktail” of immunoregulatory proteins can be contained in the present vaccines, and can be introduced to a patient according to the present methods.
- the particular immunoregulatory proteins to use in a cocktail can be determined by one skilled in the art based upon such factors as the patient being treated and the type and severity of the patient's illness.
- the cocktail can be pre-mixed and injected into a tumor bed, thereby leading to tumor suppression.
- the vaccines have been found effective in both pre-immunizing recipients against a subsequent tumor challenge and in the treatment of established tumors.
- the following example demonstrates a method for transferring a B7-1-Fc ⁇ 1 fusion protein to a cell using palmitated protein A.
- Recombinant protein A (Calbiochem, La Jolla, Calif.) was derivatized with the N-hydroxysuccinimide ester of palmitic acid (Sigma, St. Louis, Mo.) as described by Kim and Peacock, J. Immunol Methods, 158:57 (1993). Briefly, a stock solution of the N-hydroxysuccinimide ester of palmitic acid was made, as was a solution containing protein A in a concentration of about 1.5 mg/ml. The solutions were mixed in a ratio of about 10 ⁇ g ester per ml protein and incubated at room temperature with constant mixing for about 18 h. The lipid-derivatized protein A was purified as described by Huang, et al., J.
- Daudi EL-4, JY and K562 cells (3-7 ⁇ 10 6 /ml) were separately resuspended in RPMI 1640 medium (BioWittaker, Walkersville, Md.) after three washes with this same medium. Varying concentrations of pal-prot A (or nonderivatized protein A as negative control) were added to the cell suspension, and the mixture was incubated at 4° C. for 2 h with constant mixing.
- EL-4 cells were incubated with 33 ⁇ g/ml pal-prot A for the indicated periods of time and processed as above; pal-prot A incorporation was rapid, appearing immediately after addition to the cells and reaching a plateau at ⁇ 1 h, as shown in FIG. 1C.
- This data demonstrates that numerous different cell lines can be used in the present protein transfer methods, and that the lipidated protein was incorporated into the cell fairly rapidly
- the expression plasmid pCDMS/B7Ig encoding the complete human B7-1 extracellular domain linked in-frame to the Fc ⁇ 1 , was obtained from the American Type Culture Collection (Manassas, Va.).
- the sequence encoding B7-1 ⁇ Fc ⁇ 1 was mobilized from pCDM8/B7Ig by digesting with XbaI, filling-in with Klenow fragment, and subsequently digesting with HindIII.
- the mobilized fragment was subcloned into the EBV episomal expression vector pREP7 ⁇ (Invitrogen, San Diego, Calif.) with HindIII and filled-in BamHI sites.
- the plasmid was transfected into 293 cells (human kidney cell line; American Type Culture Collection), and hygromycin B-resistant colonies were selected in serum-free UltraCulture medium (BioWittaker) supplemented with 10 mM glutamine, penicillin/streptomycin, and 200 ⁇ g/ml hygromycin B.
- Secreted B7-1 ⁇ Fc ⁇ 1 was purified from conditioned medium by protein A-agarose (Life Technologies, Germantown, Md.) affinity chromatography and verified by SDS-PAGE.
- the protein was run on a 10% SDS-polyacrylamide gel and visualized with Coomassie blue as a dominant single band of ⁇ 80 kDA under both reducing (lane 2 ) and nonreducing (lane 3 ) conditions as shown in FIG. 2. Its identity was confirmed by ELISA, with a recombinant protein binding strongly to the human B7-1 specific mAb, BB-1, but not to control Ab (data not shown)
- FIG. 3A shows that when K562 cells were precoated with pal-prot A, secondarily applied B7-1 Fc ⁇ 1 attached to the cell surface, as detected by immunostaining of the cells with anti B7-1 BB-1 mAb and FITC-conjugated goat anti-mouse IgG.
- a control Fc fusion protein CD28 ⁇ Fc ⁇ 1
- B7-1 ⁇ Fc ⁇ 1 a control Fc fusion protein
- no BB-1 binding was observed, substantiating BB-1mAb's B7-1 specificity.
- underivatized protein A was substituted for pal-prot A, no BB-1 binding was observed, indicating the dependence of the lipid anchoring for fusion protein attachment.
- PBMC peripheral blood mononuclear cells
- T-cells were purified by two rounds of treatment with Lympho-kwik (One Lambda, Canoga Park, Calif.). T-cell purity was verified by lack of a proliferative response to phytohemaglutin (“PHA”)or [???] PMA in the absence of accessory cells.
- PHA phytohemaglutin
- the human CD3-specific mAb HIT3a (PharMingen) was bound to 96-well plates at the indicated concentrations and used in this form to provide a first activating signal to T-cells. Alternatively, PHA was used in soluble form as a source of a first signal.
- K562 cells transfected with the negative control vector pREP7 ⁇ (K562/pREP7 ⁇ ) were precoated with pal-prot A and secondarily coated with B7-1 ⁇ Fc ⁇ 1 .
- For each proliferation assay 1 ⁇ 10 5 T-cells were incubated with 4 ⁇ 10 4 B7-1 ⁇ Fc ⁇ 1 -coated and mitomycin C-treated K562/REP7 ⁇ cells for 60 h at 37° C. Wells were pulsed with 1 ⁇ Ci [ 3 H]thymidine for the last 16 h of the incubation period. Cells were harvested and counted on a Betaplate liquid scintillation counter.
- K562/REP7 ⁇ cells i.e., K562 cells stably transfected with the pREP7 ⁇ EBV episomal expression vector
- K562/REP7 ⁇ cells lack detectable B7-1 (data not shown) and provide a suitable negative control for experiments with K562/B7-l transfected cells (i.e., K562 cells stably transfected with a pREP7 ⁇ vector containing human B7-1 cDNA sequence).
- B7-1 levels on K562/B7-1 transfected cells and B7-1 ⁇ Fc ⁇ 1 -coated K562/REP7 ⁇ cells were determined by immunostaining, and the mean fluorescence intensities were 550 nm and 450 nm, respectively.
- B7-1 ⁇ Fc ⁇ 1 -coated K562/REP7 ⁇ cells, but not K562/REP7 ⁇ significantly enhance T-cell proliferation.
- the costimulatory effect was comparable to that achieved with K562/B7-1 transfected cells.
- the B7-1 ⁇ Fc ⁇ 1 /pal-prot A-dependence of the observed costimulation was verified by showing that cells treated with a combination of (non-derivatized) protein A and B7-1 ⁇ Fc ⁇ 1 , or with a combination of pal-prot A and control CD8 ⁇ Fc ⁇ 1 , did not enhance T-cell proliferation.
- K562/REP7 ⁇ cells also costimulate T-cell proliferation, although to a lesser extent than the B7-l positive cells.
- T-cell proliferation was observed once a threshold B7-1 ⁇ Fc ⁇ 1 concentration (0.1 ⁇ g/ml) was reached, and the level of proliferation continued to rise with increasing B7-1 ⁇ Fc ⁇ 1 concentrations until reaching a plateau at ⁇ 3.3 ⁇ g/ml.
- a threshold B7-1 ⁇ Fc ⁇ 1 concentration 0.1 ⁇ g/ml
- PHA 0.25 ⁇ g/ml
- T-cell proliferation was observed when a higher threshold B7-1 concentration (1 ⁇ g/ml) was reached, indicating that costimulator thresholds can be modulated by the strength of the first signal.
- T-cells were incubated with 5 ⁇ 10 5 processed K562/REP7 ⁇ cells (B7-1 ⁇ Fc ⁇ 1 positive or negative) in 48-well plates using either plate-bound HIT3a or PHA as a source of first signal.
- Supernatants were collected after 48 h, and ELISAs for human IFN- ⁇ and lL-2 were performed using a commercial ELISA kit according to manufacturer's protocol (Genzyme, Cambridge, Mass.). More specifically, ELISA was used to measure T-cell cytokine secretion in response to varying painted B7-1 ⁇ Fc ⁇ 1 concentrations and fixed suboptimal primary stimulus concentrations.
- the B7-1 ⁇ Fc ⁇ 1 concentrations eliciting minimal and maximal cytokine responses differed for IFN- ⁇ and IL-2 with the general hierarchy being IFN- ⁇ ⁇ IL-2, as shown in FIG. 6A.
- a similar hierarchy for the cytokine responses was observed when anti-CD3 mAb (3.3 ⁇ g/ml) was used as a source of first signal as shown in FIG. 6B.
- IFN- ⁇ output was 60% of the maximal response, whereas IL-2 output showed no increase above basal levels (FIG. 6B).
- B7-1 costimulator thresholds matches the order described for TCR activation thresholds. Having documented that B7-1 levels can modulate the extent of T-cell proliferative responses, it was then determined that B7-1 levels can also dictate the quality of immune responses by altering the ratios of cytokines produced by activated T-cells.
- the cells were thoroughly washed to remove unincorporated proteins, and subsequently incubated in suspension for up to three days at 37° C. in DMEM medium containing 10% fetal calf serum. At several intervals, aliquots of the suspension were taken and cells were pelleted. The amount of radioactive label remaining in the cell pellet was compared to the total amount of radioactive counts in the aliquot. The ratio between the two was calculated as the relative portion of the transferred protein still retained on the cell membrane. As depicted in FIG. 8, there is a direct relationship between a higher protein transfer reaction temperature and a better long-term retention rate. More importantly, by raising the transfer temperature from 4° C. to 37° C., the transferred proteins can remain membrane-bound at the physiological temperature of 37° C. for three days without significant loss (after the initial six hours).
- C3H/HeN mice purchased from Harlen (USA), Indianapolis, were inmmunized with a cell vaccine generated from the T-50 cell line, obtained from Avranham Hochberg, Hadassah University Hospital.
- the cells were coated with the lipidated protein A at 37° C. at a ratio of 40 ⁇ g protein A per 40 ⁇ 10 6 cells. The cells were then incubated at 4° with an equal mixture of the three fusion proteins at a ratio of 20 ⁇ g total protein per 4 ⁇ 10 7 cells.
- the cell vaccine was injected into the mice subcutaneously at a dose of 10 6 cells per injection. The injections were given once a week and continued for three weeks. One week after the last injection, the animals were challenged with 10 6 wild-type T-50 tumor cells, injected intradermally on the rear flank. As FIG. 9 shows, the cell vaccine improved the survival rate of the immunized animals.
- FIG. 10 shows that the cell vaccine improved the survival rate of the treated animals.
- a vaccine was formed with palmitated protein A and FasL-Fc, B7-1 ⁇ Fc, 4-1BBL ⁇ Fc and CD40L ⁇ Fc fusion proteins by mixing them in vitro at three parts of lipidated protein A and one part of each of the fusion proteins. The protein mixture was then injected intratumorally at 4 ⁇ g of total protein per tumor site. The vaccine was subsequently injected directly into a tumor; the immune costimulatory proteins in the vaccine modified the immunogenic property of tumor cells in situ.
- DBA mice were inoculated with a lethal dose of L5178Y-R tumor cells. As tumor mass grew to about 50 MM 2 in size, the cancer vaccine was injected directly into the tumor site The vaccines were pre-assembled with palmitated protein A, which confers the ability to anchor costimulators on the tumor cells in situ according to the present methods. As shown in FIG. 11, the survival of the mice treated with the indirectly lipidated costimulators was significantly prolonged.
- FasL is a cell surface protein that binds to another protein, Fas, found on the surface of other cells, for example, activated T-cells.
- FasL binds to Fas
- the cells expressing Fas undergo apoptosis.
- the FasL ⁇ Fc fusion protein after being transferred onto the cell surface through the lipidated protein A, retained its apoptotic activity.
- a standard JAM assay is performed.
- the effector cells were CHO cells that were painted with palmitated protein A (pal-prot A) and subsequently with Fc fusion protein.
- the target cells were Jurkat cells that constitutively express Fas and thus are susceptible to Fas/FasL-mediated apoptosis.
- a standard JAM assay was performed, according to the protocol described by P. Matzinger ( J. Immunol. Methods, 145:185-192,1991).
- fusion proteins can be transferred to cells both ex vivo and in situ. Significantly, these fusion proteins retain their immunoregulatory function after transfer. The examples demonstrate this retained function against post-immitation challenge and against pre-existing tumors. The methods were demonstrated as being effective both in vivo and in vitro.
Abstract
Methods for transferring one or more proteins to a cell are disclosed. The protein or proteins to be transferred are in the form of a fusion protein, and contain at least one domain encoding for a protein or peptide having trans signaling and/or adhesion function. The fusion protein is transferred to a cell by binding to a lipidated protein, which has been incorporated into the cell membrane. Methods for using cells which have undergone protein transfer according to the present methods are also disclosed. This includes use in a cancer vaccine, use for treatment of cancer or autoimmune disease, and use in determining costimulator threshold levels.
Description
- The present invention relates to novel methods for transferring one or more proteins to a cell. In addition to other applications, the methodology is useful in the treatment of cancer and autoimmune diseases, and for determining costimulator activation thresholds and cooperative interactions among costimulators.
- T-cells, including cytotoxic T-lymphocytes (CTLs), are a critical component of effective human immune responses to tumors, viral infections and other infectious diseases. T-cells destroy neoplastic or virally infected cells through recognition of antigenic peptides presented by MHC class I molecules on the surfaces of target cells. Activation of T-cells is dependent upon coordinate signaling through antigen receptors and costimulator receptors on T-cell surfaces. Many mechanisms contribute to the escape of tumor cells and virally infected cells from immune surveillance. One of the mechanisms is that these cells lack the costimulatory molecules required for T-cell activation. Immunotherapeutic strategies have been developed that are predicated upon expressing costimulators on tumor cell, and other antigen-presenting cell, surfaces.
- Professional antigen-presenting cells (APCs), by virtue of the surface costimulatory molecules, are geared towards potent T-cell activation. APCs can be converted into deletional APCs, or “artificial veto cells”, by expressing coinhibitors at their surfaces. This is discussed, for example, in U.S. Pat. Nos. 5,242,687; 5,601,828; and 5,623,056. Such coinhibitors bind to coinhibitor receptors on cells, leading to T-cell inactivation.
- One approach for expressing costimulators and coinhibitors on APCs, such as tumor cells, is gene transfer. When used for APC and tumor cell engineering, gene transfer techniques have shortcomings. For example, APCs, including tumor cells, are often poorly transfectable. In addition, transfection proceedings are cumbersome and time-consuming. Furthermore, expressing more than a costimulator (or coinhibitor) is difficult. These and other issues have impeded the widespread application of gene therapy for APC and tumor cell engineering.
- Protein transfer offers a number of advantages over gene transfer for engineering APCs and other cells. These advantages include the ability to modify poorly transfectable cells (for example, biopsy-derived tumor cells), the simplicity of expressing multiple proteins on the same cell surface, and the relative ease and rapidity of the procedure. The successful use of recombinant GPI-modified costimulator and MHC protein derivatives for protein transfer has been reported. (See, Brunschwig, et al.J. Immunol., 155:5498 (1995); McHugh, et al; Proc. Natl. Acad. Sci. USA, 92:8059 (1995); and McHugh, et al. Cancer Res., 59:2433 (1999)). A shortcoming of the GPI protein transfer strategy, however, resides in scaling up the purification of GPI proteins from membranes of transfected cells.
- Kim and Peacock,J. Immunol. Methods, 158:57 (1993), report the use of palmitate-conjugated protein A for coating cells with artificial receptors which facilitate intercellular interactions. More specifically, a method is reported for attaching an antibody onto the surface of a cell using palmitated protein A. The article does not teach use of a lipidated protein for attachment of anything other than an antibody to a cell. As such, their modified cells serve only as artificial receptors for antigens.
- Phillips et al.,Immunity, 5:163-172 (August, 1996) report the preparation of a fusion protein using a CD8 leader segment, the Fc domain, of immunoglobin and the ectodomain of a type II membrane protein, CD94. The present transfer methods are applicable to both type I and type II proteins and are neither taught nor suggested in the article.
- Darling, et al.,Gene Therapy, 4(12): 1350-60 (Dec. 1997) report the use of a biotin/avidin-based system for protein transfer. This method involves biotinylation of the target cell, attachment of an avidin group to the protein to be transferred, and combining the biotinylated target cell and the avidin-tagged protein. This method has significant limitations, including its dependence on covalent modifications that could perturb multiple proteins on cell surfaces.
- There remains a need, therefore, for methods of efficient and quantitative transfer of proteins and peptides to cells. A further need is to provide such methods in which immunoregulatory molecules that retain their function can be attached to cells of interest.
- The present invention has met the above needs, by providing methods for quantitative transfer of a domain having trans-signaling and/or adhesion function onto a cell surface. Typically, the domain will be the extracellular domain having one or both of these functions. In a preferred embodiment, the extracellular domain of an immuno-regulatory molecule is used. More specifically, the present methods provide a two-step protein transfer approach, which permits delivery of graded amounts of proteins to a cell surface. The methods utilize a fusion protein comprised of at least two domains, one of which preferably encodes a molecule having immunoregulatory function. By adding the fusion protein to cells coated with a lipidated protein, fine titration of, for example, the immunoregulatory molecule's extracellular domain is achieved.
- The present protein transfer methods have wide application. For example, the methods have been used to establish that costimulator thresholds exist, and that the levels of surface costimulator on APCs can dictate both the magnitude and the quality of evoked T-cell responses. The present methods are also applicable to the generation of cancer vaccines; these vaccines show significant anti-tumor effects in vivo. Furthermore, the methods can be used to generate artificial veto cells, expressing one or more coinhibitors, that can be used to delete pathogenic T-cells. Cells produced according to the present methods are therefore useful in the treatment of cancer and also in the treatment of autoimmune diseases. The methodologies described herein can also be used in the establishment of animal models and for the study of immunological issues regarding, for example, T-cell activation, use of costimulators to override apoptotic signals, function of coinhibitors versus costimulators, synergy of costimulators used in the treatment of cancer, and use of coinhibitors in the treatment of autoimmune diseases.
- FIG. 1, including1A, 1B and 1C, demonstrates the efficacy of coating cells with a lipidated protein, according to the methods of Example 1.
- FIG. 2 provides the SDS-PAGE analysis of recombinant B7-1·Fcγ1 prepared as described in Example 1.
- FIG. 3 demonstrates that the present methods achieve fusion protein transfer (FIG. 3A), in a quantitative manner (FIG. 3B), as described in Example 1.
- FIG. 4 demonstrates the stimulation of T-cell proliferation in the presence of various proteins (as indicated) using either PHA (FIG. 4A) or anti-CD3 mAb (FIG. 4B) as a first signal, as described in Example 1.
- FIG. 5 demonstrates B7-1 threshold concentrations for T-cell proliferation using either PHA (FIG. 5A) or anti-CD3 mAb (FIG. 5B) as a first signal, as described in Example 1.
- FIG. 6 provides a comparison of B7 concentration thresholds for IFN-γ versus IL-2 production using either PHA (FIG. 6A) or anti-CD3 mAb (FIG. 6B) as a first signal, as described in Example 1.
- FIG. 7 provides comparative single-cell analyses of B7-1 concentration thresholds for IFN-γ versus IL-2, as described in Example 1.
- FIG. 8 shows the effect of reaction temperature during protein transfer on the stability of transferred protein, as described in Example 2.
- FIG. 9 demonstrates the efficacy of the present cancer vaccines in protecting a patient against a post-immunization tumor challenge, as described in Example 3.
- FIG. 10 demonstrates the efficacy of the present cancer vaccines in treating a pre-existing tumor, as described in Example 4.
- FIG. 11 demonstrates the efficacy of the present cancer vaccines by intratumoral injection of costimulators, as described in Example 5.
- FIG. 12 shows the results of the JAM assay, as described in Example 6.
- The present invention is directed to methods for transferring one or more proteins to a cell, generally comprising the steps of coating the surface of a cell with a first protein, which is a lipidated protein, and contacting the coated cell with a second protein, which is a fusion protein. The fusion protein is comprised of a first domain having affinity for the lipidated protein and a second domain of a peptide, protein, or derivative or fragment thereof, having trans signaling and/or adhesion function. Preferably, the extracellular domain is used, and the second domain has immunoregulatory function. “Derivative”, as used in reference to peptides and proteins, refers to variants of peptides and proteins such as analogues wherein, for example, one or more amino acids within the peptide chain has been deleted, added or replaced with an alternative amino acid. A “fragment” refers to a portion of the amino acid sequence of a peptide or protein. It will be understood that “derivatives” and “fragments” of peptides and proteins retain the physiological function of the wild type peptide or protein and thus are biologically active.
- The present methods are applicable to any cell having a lipid bilayer membrane. For example, any kind of a patient's autologous cells can be used, harvested by any means known in the art. Use of any allogeneic mammalian cell line is also within the scope of the present invention. Examples of allogeneic cell lines suitable for use in the present invention include, but are not limited to, EL-4 cells (mouse thymoma cells), 293 cells (human kidney cells), K562 cells (human leukemia cells), Daudi cells (human B cell line) and JY cells (human B cell line). These cells are commercially available from the American Type Culture Collection, Manassas, VA. Non-commercially available cell lines are also within the scope of the present invention.
- Any protein that can be lipidated is suitable for use in the present methods. Examples include, but are not limited to, protein A and protein G, both of which are commercially available. Similarly, any lipid can be used to prepare the lipidated protein. Lipids having carbon chains between about 12 and 22 are preferred, with a carbon chain of 16 (palmitate) being most preferred. The length of the lipid chain can be varied based upon the needs and desires of the user. It will be understood to those skilled in the art that the lipidated portion of the first protein will become attached to or incorporated into the phospholipid bilayer that makes up the membrane of the cell, and that this is what is meant by the phrase “coating the surface of the cell” as that phrase is used herein.
- The amount of lipidated protein used to coat the cell may also vary based on the needs and desires of the user, and based on the particular lipid and particular protein selected Preferably, enough lipidated protein is used to coat the entire cell. This amount will typically be at least about 30 micrograms of lipidated protein for every 5×106 cells.
- Following coating of the cells, the cells are then contacted with a second protein. The second protein is a fusion protein in which two different domains have been fused, such as through recombinant DNA technology standardly used in the art, to create a single DNA sequence. The first domain can be attached at either the amino terminus or the carboxyl terminus of the fusion protein. The first domain encodes a peptide, protein, or derivative or fragment thereof, what has affinity for the lipidated protein. Thus, the protein used in the lipidated protein is ideally selected in conjunction with the protein encoded by the first domain of the fusion protein, so that proteins having affinity for one another are used. Affinity between the proteins can be determined by Biacore technology or other methods familiar in the art. Because of this affinity, the fusion protein binds to the lipidated protein, which has already been incorporated into the cell membrane. In this manner, the fusion protein is transferred to the cell. A particularly preferred combination uses a palmitated protein A and a first domain encoding an Fc region. For example, the Fc region of human immunoglobulin G1 (IgG1), designated Fcγ1, can be used. Other suitable first domains in the fusion protein include leucine zipper protein domains and single-chain Fv derivative domains.
- The second domain of the fusion protein encodes a peptide, protein, or derivative or fragment thereof, having immunoregulatory function and capable of tranes signaling to a second cell. Examples include, but are not limited to, costimulators and coinhibitors. Any suitable costimulator can be used including but not limited to B7-1, B7-2, CD48, ICAM-1, ICAM-2, ICAM-3, LFA-3, CD30 Ligand (CD30L), CD40 Ligand (CD40L), 4-IBB Ligand (4-1BBL), and heat stable antigen. Similarly, any suitable coinhibitor can be used including, but not limited to, CD8, FasL and PP14.
- Significantly, the fusion protein of the present invention can be either a type I or type II protein. Methods for transferring a type II protein to a cell have never been reported. Because the methods of the present invention are equally applicable to type I and type II proteins, they provide a significant advance over the art. Examples of type I membrane proteins include B7-1, B7-2 and CD48; examples of type II membrane proteins include Fas ligand (FasL or CD95L), CD40L, and 4-1BBL. For the type II proteins, the first domains are fused at the carboxyl termini of the type II proteins in order to preserve the functional ends of the molecules. These lists are not exhaustive of the costimulators, coinhibitors and other proteins that can be transferred according to the present invention; the lists reflect all forms of the various molecules including, but not limited to, human and murine forms.
- Another significant advance provided by the present methods is that following transfer of the fusion protein to the cell, the portion of the fusion protein having trans signaling function retains this function. Thus, the cells prepared according to the present methods are capable of eliciting an immune response by binding to, and trans signaling through a counter-receptor on a second cell.
- In addition, more than one fusion protein can be used to coat a single cell. In this manner, two, three, four, or more trans signaling, for example, immunoregulatory proteins, can be transferred to a cell. In the case of costimulators and coinhibitors, combinations of such proteins can be chosen to have the greatest immunological effect; combinations having additive or even synergistic benefits can be selected and used according to the present methods.
- The present methods are further unique in that proteins can be delivered to a cell's surface in a quantitative manner. As noted above, it is preferred to use enough lipidated protein to fully coat the cell. The amount of fusion protein that becomes transferred to the cell is therefore determined by the amount of fusion protein used to contact the coated cell; thus the amount of fusion protein is the limiting or determinative factor. When using more than one fusion protein, predetermined ratios of fusion proteins can be used to contact the coated cell; protein will be transferred to the cell in these approximate ratios.
- The present methods can be effected either in vivo or in vitro. In in vivo methods, the lipidated protein and the fusion protein are injected directly into a patient. The injection can occur sequentially (with the lipidated protein first) or concurrently, with premixing of the lipidated protein and the fusion protein(s). Injection can be localized, for example, intra-tumoral, or systemic, for example, into a vessel. The present methods, and cells produced thereby, in contrast to other art-reported methods, have particularly high protein stability, making the present method practical for in vivo application. In vitro methods involve the extraction of cells from a patient, and the subsequent coating and contacting of the cells; alternatively, commercially obtained allogeneic cells can be used. In either case, the treated cells can then be injected into a patient.
- All of the above descriptions relating to cell type, first proteins, second proteins, and in vivo, in vitro and other delivery techniques apply equally to all embodiments of the invention disclosed herein.
- The present invention is further directed to methods for determining costimulator activation thresholds in T-cells. These methods generally comprise transferring one or more fusion proteins to a cell, in the manner described above. The cells to which protein has been transferred are then mixed with T-cells. T-cells can be, for example, harvested from peripheral blood mononuclear cells by methods known in the art. T-cell proliferation, if any, can be measured, as can cytokine secretion levels according to means known in the art, such as those described in the Example section.
- The present invention is further directed to methods for treating an illness using the present protein transfer technology. These methods generally comprise administering to a patient an effective amount of the cells prepared in vitro according to the method described above, or administering the proteins in vivo. The method can be performed by either in vivo or in vitro protein transfer of the fusion protein(s) to the target cells. For in vitro methods, either extracted autologous cells or allogeneic cells are coated with a lipidated protein and contacted with one or more fusion proteins. An effective amount of these cells are then administered to a patient. For in vivo methods, lipidated protein and one or more fusion proteins are administered to a patient in an amount sufficient to result in transfer of an effective amount of fusion protein(s) to an effective amount of cells.
- “Illness” as used herein refers to cancer and autoimmune and alloimmune diseases, including but not limited to arthritis, rheumatoid arthritis, asthma, graft-versus-host disease, organ rejection, systemic lupus erythematosis, atopic allergy, inflammatory bowel disease, multiple sclerosis and allergic dermatitis. The methods are particularly applicable to treatment of cancer, in that the lipidated protein and fusion protein(s) in the in vivo methodology, or the coated and contacted cells in the in vitro methodology, can be directly injected into one or more tumors of the patient. “Patient” is used herein to refer to members of the animal kingdom, including humans. The present methods are generally applicable to patients capable of generating at least a minimal immune response.
- An effective amount of cells produced by the present protein transfer methods should be used in the present treatment methods. The effective amount is that amount of cells that will deliver the amount of protein to a patient needed to bring about a desired result Generally, the desired result can be, for example, stimulation of an immune response or suppression of an immune response. In the case of cancer treatment, an effective amount would be that amount which would protect a patient against tumor growth or reduction, if not elimination, of tumors. In the case of autoimmune or alloimmune disease, an effective amount would be that amount which would alleviate if not eliminate one or more symptoms of the autoimmune or alloimmune disease being treated. It will be understood that the effective amount will vary from patient to patient depending on such factors as the patient's size, the condition of the patient's immune system, the patient's ability to mount an immune response, and the type and severity of the illness. The appropriate effective amount for each patient can be determined by one skilled in the art, and will generally be at least about 107 modified cells or 100 μg Fc fusion protein intratumorally.
- The present invention is further directed to a cancer vaccine comprising cells prepared according to the present protein transfer methods contained in a suitable carrier. Any suitable carrier can be used, provided compatibility problems do not arise. Examples include PBS, and serum-free medium. The vaccine can include a variety of fusion proteins; different cells each having a different fusion protein, or cells having more than one fusion protein attached thereto, can be used for example. Thus, a “cocktail” of immunoregulatory proteins can be contained in the present vaccines, and can be introduced to a patient according to the present methods. The particular immunoregulatory proteins to use in a cocktail can be determined by one skilled in the art based upon such factors as the patient being treated and the type and severity of the patient's illness. Different combinations could be used to treat different types of tumors. The cocktail can be pre-mixed and injected into a tumor bed, thereby leading to tumor suppression. The vaccines have been found effective in both pre-immunizing recipients against a subsequent tumor challenge and in the treatment of established tumors.
- The present examples are intended to illustrate the invention and should not be construed as limiting the invention in any way.
- The following example demonstrates a method for transferring a B7-1-Fcγ1 fusion protein to a cell using palmitated protein A.
- Palmitation of protein A
- Recombinant protein A (Calbiochem, La Jolla, Calif.) was derivatized with the N-hydroxysuccinimide ester of palmitic acid (Sigma, St. Louis, Mo.) as described by Kim and Peacock,J. Immunol Methods, 158:57 (1993). Briefly, a stock solution of the N-hydroxysuccinimide ester of palmitic acid was made, as was a solution containing protein A in a concentration of about 1.5 mg/ml. The solutions were mixed in a ratio of about 10 μg ester per ml protein and incubated at room temperature with constant mixing for about 18 h. The lipid-derivatized protein A was purified as described by Huang, et al., J. Biol. Chem., 225:8015 (1980) using a 30-ml Sephadex G-25 (Sigma) column. The protein product, referred to herein as “pal-prot A”, was quantitated using a bicinchoninic acid kit (Bio-Rad, Richmond, Calif.), filter sterilized, and stored at 4° C. until use.
- Membrane incorporation of pal-prot A
- Daudi EL-4, JY and K562 cells (3-7×106/ml) were separately resuspended in RPMI 1640 medium (BioWittaker, Walkersville, Md.) after three washes with this same medium. Varying concentrations of pal-prot A (or nonderivatized protein A as negative control) were added to the cell suspension, and the mixture was incubated at 4° C. for 2 h with constant mixing. To assess the incorporation of pal-prot A onto cell surfaces, cells were washed twice in buffer (0.25% BSA/0.01% sodium azide/PBS) and then incubated on ice for 1 h with 100 μl of 100 μg/ml FITC-human IgG (Sigma) diluted with the same buffer. Cells were washed twice in the buffer and analyzed on a FACStar® flow cytometer (Becton Dickinson, Mountain View, Calif.).
- In a first set of optimization experiments, efficient incorporation of pal-prot A was documented in four cell lines (FIG. 1A) as detected with FITC-conjugated human IgG. As a negative control, nonderivatized protein A lacked the capacity to bind to the same cells. Data from the FACStar analysis was plotted as arbitrary units of log10 fluorescence intensity versus number of EL-4 cells; membrane incorporation was dose dependent and started to plateau at about 33 μg/ml pal-prot A, as shown in FIG. 1B. EL-4 cells were incubated with 33 μg/ml pal-prot A for the indicated periods of time and processed as above; pal-prot A incorporation was rapid, appearing immediately after addition to the cells and reaching a plateau at ˜1 h, as shown in FIG. 1C. This data demonstrates that numerous different cell lines can be used in the present protein transfer methods, and that the lipidated protein was incorporated into the cell fairly rapidly
- Preparation of recombinant B7-1·Fcγ1
- The expression plasmid pCDMS/B7Ig, encoding the complete human B7-1 extracellular domain linked in-frame to the Fcγ1, was obtained from the American Type Culture Collection (Manassas, Va.). The sequence encoding B7-1·Fcγ1 was mobilized from pCDM8/B7Ig by digesting with XbaI, filling-in with Klenow fragment, and subsequently digesting with HindIII. The mobilized fragment was subcloned into the EBV episomal expression vector pREP7β (Invitrogen, San Diego, Calif.) with HindIII and filled-in BamHI sites. The plasmid was transfected into 293 cells (human kidney cell line; American Type Culture Collection), and hygromycin B-resistant colonies were selected in serum-free UltraCulture medium (BioWittaker) supplemented with 10 mM glutamine, penicillin/streptomycin, and 200 μg/ml hygromycin B. Secreted B7-1·Fcγ1 was purified from conditioned medium by protein A-agarose (Life Technologies, Germantown, Md.) affinity chromatography and verified by SDS-PAGE. The protein was run on a 10% SDS-polyacrylamide gel and visualized with Coomassie blue as a dominant single band of ˜80 kDA under both reducing (lane 2) and nonreducing (lane 3) conditions as shown in FIG. 2. Its identity was confirmed by ELISA, with a recombinant protein binding strongly to the human B7-1 specific mAb, BB-1, but not to control Ab (data not shown)
- B7-1·Fcγ1 protein transfer
- Cells precoated with pal-prot A were washed once and resuspended in RPMI 1640 medium (3-7×16 cells/ml). pREP7B-transfected K562 cells (K562/REP7b) were serially incubated with 33 μg/ml protein A for 2 h, 33 μg/ml Fcγ1 fusion protein for 1 h, and BB-1 as primary Ab and FITC-conjugated goat anti-mouse IgG as secondary Ab. To monitor protein delivery, 106 cells were washed twice with the same buffer as above, incubated on ice for 1 h with 1 μg of human B7-specific mAb BB-1 (PharMingen, San Diego, Calif.) in 100 μl of buffer. Cells were washed once and immunostained (on ice for 1 h) with 100 μl of 1:100 diluted FITC-conjugated goat F(ab′)2 anti-mouse Ig (Boehringer Mannheim, Indianapolis, Ind.) as secondary Ab. Cells were washed once, resuspended in PBS, and analyzed on a FACStar flow cytometer.
- FIG. 3A shows that when K562 cells were precoated with pal-prot A, secondarily applied B7-1 Fcγ1 attached to the cell surface, as detected by immunostaining of the cells with anti B7-1 BB-1 mAb and FITC-conjugated goat anti-mouse IgG. When a control Fc fusion protein (CD28·Fcγ1) was substituted for B7-1·Fcγ1, no BB-1 binding was observed, substantiating BB-1mAb's B7-1 specificity. When underivatized protein A was substituted for pal-prot A, no BB-1 binding was observed, indicating the dependence of the lipid anchoring for fusion protein attachment.
- Quantitation of exogenously incorporated B7-1·Fcγ1 at cell surfaces
- Human B7-1·Fcγ7was iodinated using Iodo-beads (Pierce, Rockford, Ill.) according to the manufacturer's protocol, and the labeled protein was purified on a Sephadex G-25 column (Pharmacia, Piscataway, N.J.). The specificity was adjusted to 2.1×106 cpm/Ig by addition of unlabeled B7-1 ·Fcγ1. Protein transfer was performed as described earlier, substituting the labeled protein. All experiments were performed in duplicate. To control for nonspecific binding, excess amounts of unlabeled human IgG (Sigma) were added to specifically block the binding of B7-1·Fcγ1 to protein A. After repeated washing, counts in cell pellets were determined using a gamma counter (1272 Clinigamma; LKB Instruments, Gaithersburg, Md.). Counts resulting from specific binding of B7-1·Fcγ1 were calculated by subtracting nonspecific counts obtained with human IgG. The average number of molecules on a single cell was calculated according to the formula A×B−1×C−1×NA, where A is the determined radioactivity (cpm) in the cell pellet, B is the specific activity of the labeled protein expressed as cpm/mol, C is the number of cells in the cell pellet, and NA is Avogadro's constant.
- As shown in FIG. 3B, when K562 cells were precoated with excess amounts of pal-prot A (33 μg/ml), surface levels of B7-1·Fcγ1 were dependent on the concentrations of applied B7-1·Fcγ1. Surface B7-1 epitope levels started to plateau at 33 μg/ml, and the epitope density was similar to that on B7-1 transfected K562 cells (data not shown). The average number of B7-1·Fcγ1 painted per cell was determined using 125I-labeled B7-1·Fcγ1. Again, K562 cells incorporated increasing amounts of B7-1·Fcγ1 as the reagent concentration was increased during the painting process, as shown in Table I.
TABLE 1 Painting of B7-1 · Fcγ1 onto K562 cells B7-1 Fcγ1 No. of B7-1 · Fcγ1/cellb (μg/ml)a (mean ± SD) 0.033 460 ± 240 0.33 9,900 ± 1,200 3.3 92,000 ± 8,300 33 460,000 ± 34,000 - At the lowest concentration used (0.033 μg/ml), ˜460 molecules became anchored onto each K562 cell. At the highest concentration used (33 μg/ml), about 460,000 B7-1·Fcγ1 molecules became incorporated. Taken together, these data establish that B7-1·Fcγ1 can be applied to pal-prot A-coated cells in a quantitative fashion.
- Proliferation assays
- PBMC were isolated from fresh whole blood by Ficoll density centrifugation. T-cells were purified by two rounds of treatment with Lympho-kwik (One Lambda, Canoga Park, Calif.). T-cell purity was verified by lack of a proliferative response to phytohemaglutin (“PHA”)or [???] PMA in the absence of accessory cells. The human CD3-specific mAb HIT3a (PharMingen) was bound to 96-well plates at the indicated concentrations and used in this form to provide a first activating signal to T-cells. Alternatively, PHA was used in soluble form as a source of a first signal. K562 cells transfected with the negative control vector pREP7β (K562/pREP7β) were precoated with pal-prot A and secondarily coated with B7-1·Fcγ1. For each proliferation assay, 1×105 T-cells were incubated with 4×104 B7-1·Fcγ1-coated and mitomycin C-treated K562/REP7β cells for 60 h at 37° C. Wells were pulsed with 1 μCi [3H]thymidine for the last 16 h of the incubation period. Cells were harvested and counted on a Betaplate liquid scintillation counter.
- In the proliferation assays, PHA and B7-1·Fcγ1-coated K562/REP7β cells (i.e., K562 cells stably transfected with the pREP7β EBV episomal expression vector) were used to provide first and second signals, respectively, to T-cells. K562/REP7β cells lack detectable B7-1 (data not shown) and provide a suitable negative control for experiments with K562/B7-l transfected cells (i.e., K562 cells stably transfected with a pREP7β vector containing human B7-1 cDNA sequence). Surface B7-1 levels on K562/B7-1 transfected cells and B7-1 ·Fcγ1-coated K562/REP7β cells were determined by immunostaining, and the mean fluorescence intensities were 550 nm and 450 nm, respectively. As shown in FIG. 4A, in the presence of suboptimal PHA concentrations (<0.5 μg/ml), B7-1·Fcγ1-coated K562/REP7β cells, but not K562/REP7β, significantly enhance T-cell proliferation. The costimulatory effect was comparable to that achieved with K562/B7-1 transfected cells. The B7-1·Fcγ1/pal-prot A-dependence of the observed costimulation was verified by showing that cells treated with a combination of (non-derivatized) protein A and B7-1·Fcγ1, or with a combination of pal-prot A and control CD8 ·Fcγ1, did not enhance T-cell proliferation. In the presence of higher PHA concentrations (>1 μg/ml), K562/REP7β cells also costimulate T-cell proliferation, although to a lesser extent than the B7-l positive cells.
- To further confirm the costimulatory function of cell-associated B7-1·Fcγ1, proliferation assays were performed in which plate-bound anti-human CD3 mAb was substituted for PHA as a more physiological first signal. In this setting, in the presence of sub-optimal concentrations of anti-CD3 mAb (<10 μg/ml) cell-associated B7-1·Fcγ1 costimulated even more effectively than native B7-1 expressed at equivalen levels on transfected cells, as shown in FIG. 4B. Again, CD8·Fcγ1, used as a negative control Fc fusion protein, did not costimulate under the same conditions. Taken together, these results establish that B7-1·Fcγ1, tethered to membranes via pal-prot A, effectively costimulates T-cell proliferation.
- Effective depletion of accessory cells was documented in all T-cell preparations by demonstrating the lack of response to PMA or PHA in the absence of a source for costimulation. Points shown in FIGS. 4A and B are the means and SEs of triplicate samples. The data are representative of at least three independent experiments with similar results.
- Concentration-dependence of cell-associated B7-1·Fcγ1's costimulatory activity
- With an effective costimulator protein transfer method in hand, quantitative aspects of B7-1 costimulation were evaluated. To this end, T-cell proliferation assays were performed using K562/REP7β cells painted with variable concentrations of B7-1·Fcγ1. The concentration dependence of B7-1·Fcγ1-mediated costimulation could be readily demonstrated when a fixed suboptimal concentration of PHA (0.25 or 0.5 μg/ml) was used as a source of first signal, as shown in FIG. 5A. For example, in the presence of 0.5 μg/ml PHA, T-cell proliferation was observed once a threshold B7-1·Fcγ1 concentration (0.1 μg/ml) was reached, and the level of proliferation continued to rise with increasing B7-1·Fcγ1 concentrations until reaching a plateau at ˜3.3 μg/ml. In the presence of a lower concentration of PHA (0.25 μg/ml), T-cell proliferation was observed when a higher threshold B7-1 concentration (1 μg/ml) was reached, indicating that costimulator thresholds can be modulated by the strength of the first signal.
- Similar results were obtained when anti-human CD3 mAb was used as a source of first signal instead of PHA, as shown in FIG. 5B. Again, in the presence of a fixed suboptimal concentration of plate-bound anti-CD3 mAb (0.37 or 1.1 μg/ml), costimulation was observed only after a threshold B7-1·Fcγ1 concentration was reached, and a further dose-dependent increase in proliferation was also seen. Hence, in the presence of a suboptimal first signal (whether PHA or anti-CD3 mAb), a threshold B7 level is required for T-cells to proliferate and the extent of T-cell proliferation is dictated by the costimulator level.
- ELISA measurement of secreted cytokines and determination of a hierarchy of B7-1 costimulator thresholds for distinct cytokine responses
- A total of 106 T-cells was incubated with 5×105 processed K562/REP7β cells (B7-1·Fcγ1 positive or negative) in 48-well plates using either plate-bound HIT3a or PHA as a source of first signal. Supernatants were collected after 48 h, and ELISAs for human IFN-γ and lL-2 were performed using a commercial ELISA kit according to manufacturer's protocol (Genzyme, Cambridge, Mass.). More specifically, ELISA was used to measure T-cell cytokine secretion in response to varying painted B7-1·Fcγ1 concentrations and fixed suboptimal primary stimulus concentrations. At a fixed PHA dose, the B7-1·Fcγ1 concentrations eliciting minimal and maximal cytokine responses differed for IFN-γ and IL-2 with the general hierarchy being IFN-γ <IL-2, as shown in FIG. 6A. A similar hierarchy for the cytokine responses was observed when anti-CD3 mAb (3.3 μg/ml) was used as a source of first signal as shown in FIG. 6B. For instance, at a B7-1·Fcγ1 concentration of 0.33 μg/ml, IFN-γ output was 60% of the maximal response, whereas IL-2 output showed no increase above basal levels (FIG. 6B). This observed IFN-γ >IL-2 hierarchy for B7-1 costimulator thresholds matches the order described for TCR activation thresholds. Having documented that B7-1 levels can modulate the extent of T-cell proliferative responses, it was then determined that B7-1 levels can also dictate the quality of immune responses by altering the ratios of cytokines produced by activated T-cells.
- Analysis of intracellular cytokine production and evaluation of evidence for hierarchical costimulator thresholds for cytokine responses at the single-cell level
- To substantiate the ELISA findings with bulk T-cell populations, multiparameter flow cytometric analyses were performed to assess intracellular IFN-γ and IL-2 levels within individual cells. A total of 106 T-cells was incubated with 5×105 B7-1·Fcγ1-coated K562/REP7β cells in 48-well plates for 48 h. Again, either plate-bound HIT3a or PHA was used as a source of first signal. Monesin (Sigma) was added to a final concentration of 3 μM, and the mixture was incubated for an additional 6 h to accumulate cytokine within the cells. Cells were then collected, fixed by incubating them in 100 μl of fixation solution [4% paraformaldehyde/PBS (pH 7.4)] on ice for 20 min. and then washed twice with staining buffer (0.1% saponin/1% heat-inactivated FCS/0.1% sodium azide/Dulbecco's PBS). Immunostaining for intracellular cytokines was performed by incubating the cells on ice for 1 h with 100 μl of the staining buffer containing 0.5 μg of FITC-anti-IFN-γ and 0.5 μg of PE-anti-IL-2 Abs (PharMingen). Cells were subsequently washed once with staining buffer without saponin. T-cells were gated using forward light scatter/side light scatter parameters, and 2-5×104 cells were analyzed in each run.
- At low B7-1·Fcγ1 concentrations, the T-cell response was dominated by IFN-γ-only producers; however, at higher B7-1·Fcγ1 concentrations, substantial numbers of IFN-γ and IL-2 double producers emerged (FIG. 7). Relatively few IL-2 only producers were observed, even at the highest B7-1·Fcγ1 concentrations. These findings are consistent with the bulk T-cell cytokine response data, showing that an IFN-β response requires less B7-1 costimulators than does an IL-2 response.
- The effect of temperature on membrane-incorporated protein A was studied; the transferred protein must remain cell-bound in vivo in order to prime T-cells, which requires stable engagement of costimulators for at least several hours. It was determined that the reaction temperature at which a lipidated protein is transferred to the cell membrane has a major impact on long-term retention of the protein on the membrane. Protein transfer reactions were performed at 4° C., 25° C. or 37° C.; palmitated protein A was transferred onto K562 cells. An hB7-1·Fc was125I-labeled and transferred to the protein A-coated cells in the manner described in Example 1. To prevent interference of endocytosis likely to occur at temperatures above 4° C., the cells were treated with the metabolic inhibitors sodium azide and 2-deoxyglucose prior to the transfer reaction.
- To determine the long-term retention of the transferred protein on the cell membrane, the cells were thoroughly washed to remove unincorporated proteins, and subsequently incubated in suspension for up to three days at 37° C. in DMEM medium containing 10% fetal calf serum. At several intervals, aliquots of the suspension were taken and cells were pelleted. The amount of radioactive label remaining in the cell pellet was compared to the total amount of radioactive counts in the aliquot. The ratio between the two was calculated as the relative portion of the transferred protein still retained on the cell membrane. As depicted in FIG. 8, there is a direct relationship between a higher protein transfer reaction temperature and a better long-term retention rate. More importantly, by raising the transfer temperature from 4° C. to 37° C., the transferred proteins can remain membrane-bound at the physiological temperature of 37° C. for three days without significant loss (after the initial six hours).
- C3H/HeN mice, purchased from Harlen (USA), Indianapolis, were inmmunized with a cell vaccine generated from the T-50 cell line, obtained from Avranham Hochberg, Hadassah University Hospital. The vaccine was prepared following the procedure generally outlined in Example 1, using palmitated protein A and mB7-1·Fc, m4=1BBL·Fc, and hCD40L·Fc fusion proteins. Basically, the cells were coated with the lipidated protein A at 37° C. at a ratio of 40 μg protein A per 40×106 cells. The cells were then incubated at 4° with an equal mixture of the three fusion proteins at a ratio of 20 μg total protein per 4×107 cells. The cell vaccine was injected into the mice subcutaneously at a dose of 106 cells per injection. The injections were given once a week and continued for three weeks. One week after the last injection, the animals were challenged with 106 wild-type T-50 tumor cells, injected intradermally on the rear flank. As FIG. 9 shows, the cell vaccine improved the survival rate of the immunized animals. In FIG. 9: open circle, an untreated control group (n=6); square, another control group that received a control vaccine generated by protein A transfer (n=5); closed circle, the test group that received a cell vaccine generated by protein transfer with immune costimulatory proteins B7-1, 4-1BBL, and CD40L in complex with protein A (n=6).
- DBA/2J mice were purchased from The Jackson Laboratory, Maine. The animals were inoculated intradermally with a letahl dose of L5178Y-R tumor cells and given subcutaneous injections of a cell vaccine as a treatment on
days - A vaccine was formed with palmitated protein A and FasL-Fc, B7-1·Fc, 4-1BBL·Fc and CD40L·Fc fusion proteins by mixing them in vitro at three parts of lipidated protein A and one part of each of the fusion proteins. The protein mixture was then injected intratumorally at 4 μg of total protein per tumor site. The vaccine was subsequently injected directly into a tumor; the immune costimulatory proteins in the vaccine modified the immunogenic property of tumor cells in situ.
- DBA mice were inoculated with a lethal dose of L5178Y-R tumor cells. As tumor mass grew to about 50 MM2 in size, the cancer vaccine was injected directly into the tumor site The vaccines were pre-assembled with palmitated protein A, which confers the ability to anchor costimulators on the tumor cells in situ according to the present methods. As shown in FIG. 11, the survival of the mice treated with the indirectly lipidated costimulators was significantly prolonged. In FIG. 11: open circle, an untreated control group (n=6); square, another control group that were injected with lipidated protein A alone (n=7); closed circle, the test group that were injected with the immune costimulatory fusion proteins in complex with lipidate protein A (n=7).
- To generate a fusion protein for FasL, a coding sequence for a human Fcγ1 domain, obtained from ATCC, was fused at the N-terminus of the coding sequence for the extracellular domain of FasL following the fusion strategy reported in Immunity, 5:163, 1996. The purified fusion protein was fully functional, as determined by a standard killing assay when loaded on protein A-coated cells. FasL is a cell surface protein that binds to another protein, Fas, found on the surface of other cells, for example, activated T-cells. When FasL binds to Fas, the cells expressing Fas undergo apoptosis. Significantly, the FasL·Fc fusion protein, after being transferred onto the cell surface through the lipidated protein A, retained its apoptotic activity.
- More specifically to determine whether the Fc-hFasL fusion protein was functional after anchoring onto cell surfaces, a standard JAM assay is performed. The effector cells were CHO cells that were painted with palmitated protein A (pal-prot A) and subsequently with Fc fusion protein. The target cells were Jurkat cells that constitutively express Fas and thus are susceptible to Fas/FasL-mediated apoptosis. A standard JAM assay was performed, according to the protocol described by P. Matzinger (J. Immunol. Methods, 145:185-192,1991). Briefly, 2×104 3H-thymidine-labeled target Jurkat cells were co-incubated with 2×105 CHO cells (from ATCC) that were pre-coated with pal-prot A as previously described in Example 1, and subsequently painted with 30 μg/ml of Fc-hFasL fusion protein or control fusion protein. The cells were co-cultured in 200 μl of RPMI-10 in a 96-well plate for 18 hours at 37° C. in a humidified incubator at 5% CO2. To harvest the JAM test, the cells and their medium were aspirated onto fiber glass filters using a harvester (as used in Example 1 for the proliferation assays). % specific killing was calculated as follows: (S-E)/S×100, where S=spontaneous release without effector cell, E=experimental release in the presence of effector cells.
- The results are summarized in FIG. 12. When CHO cells that were painted with pal-prot A and Fc-hFasL were used as effector cells, significant killing was observed. As negative controls, when CHO cells were painted with pal-prot A and control Fe fusion protein (hCD80-Fc or hCD28-Fc), no specific killing was observed. The surface anchorage-dependence of Fc-hFasL was demonstrated by the negative control where the CHO cells were painted with unpalmitated protein A and Fc-FasL. The specificity of the killing was demonstrated by complete blockade of the killing by FasL neutralizing mAb NOK-1, whereas the control Ab did not block the killing.
- In summary, these results demonstrate that Fc-hFasL, after being transferred onto cell surface through pal-prot A, retains its function to elicit apoptosis in Fas-positive Jurkat cells.
- The above examples demonstrate the efficacy of the present methods. Through the use of lipidated proteins, fusion proteins can be transferred to cells both ex vivo and in situ. Significantly, these fusion proteins retain their immunoregulatory function after transfer. The examples demonstrate this retained function against post-immitation challenge and against pre-existing tumors. The methods were demonstrated as being effective both in vivo and in vitro.
- Whereas particular embodiments of this invention have been described above for purposes of illustration, it will be evident to those skilled in the art that numerous variations of the details of the present invention may be made without departing from the invention as defined in the appended claims.
Claims (50)
1. A method for transferring a protein to a cell comprising:
coating the surface of said cell with a first protein, wherein said first protein is a lipidated protein; and
contacting said cell with a second protein, wherein said second protein is a fusion protein comprised of a first domain having affinity for said first protein and a second domain of a peptide, protein, or derivative or fragment thereof, having trans signaling and/or adhesion function.
2. The method of claim 1 , wherein either or both of said first domain and said second domain is an extracellular domain.
3. The method of claim 1 , wherein said second domain has immunoregulatory function.
4. The method of claim 1 , wherein the amount of protein transferred to said cell is determined by the amount of second protein used in said contacting step.
5. The method of claim 1 , wherein said first protein is lipidated with a C12-C22 lipid.
6. The method of claim 5 , wherein said lipid is C16.
7. The method of claim 1 , wherein said first protein is selected from the group consisting of lipidated protein A and lipidated protein G.
8. The method of claim 7 , wherein said first protein is palmitated protein A.
9. The method of claim 1 , wherein said first domain is attached at the amino terminus of said second protein.
10. The method of claim 1 , wherein said first domain is attached at the carboxyl terminus of said second protein.
11. The method of claim 1 , wherein said second domain encodes a portion of a type I membrane protein.
12. The method of claim 1 , wherein said second domain encodes a portion of a type II membrane protein.
13. The method of claim 1 , wherein said second domain encodes a costimulator.
14. The method of claim 1 , wherein said second domain encodes a coinhibitor.
15. The method of claim 13 , wherein said costimulator is selected from the group consisting of B7-1, B7-2, ICAM-1, ICAM-2, ICAM-3, CD48, LFA-3, 4-1BB ligand, CD30 ligand, CD40 ligand, and heat stable antigen.
16. The method of claim 15 , wherein said second protein is B7-1·Fcγ1.
17. The method of claim 14 , wherein said coinhibitor is selected from the group consisting of CD8, Fas ligand, and a single-chain Fv derivative of immunoglobulin.
18. The method of claim 1 , wherein said coated cell is contacted with more than one type of second protein, and each type of second protein is different.
19. The method of claim 18 , wherein said second proteins are introduced in a predetermined ratio.
20. The method of claim 1 , wherein said coating step and said contacting step take place in vivo.
21. The method of claim 1 , wherein said coating step and said contacting step take place in vitro.
22. The method of claim 18 , further comprising the step of injecting said contacted cells into a patient.
23. A cell produced according to the method of claim 1 .
24. A method for determining costimulator activation thresholds in T-cells comprising:
a) coating the surface of a plurality of cells with a first protein, wherein said first protein is a lipidated protein;
b) contacting said cells with a second protein, wherein said second protein is a fusion protein comprised of a first domain having affinity for said first protein and a second domain of a costimulator;
c) mixing the contacted cells of step b with T-cells; and
d) determining the level of T-cell proliferation.
25. The method of claim 21 , further comprising the step of e) determining cytokine secretion levels.
26. A method for treating a patient for an illness comprising:
coating the surface of a plurality of cells with a first protein, wherein said first protein is a lipidated protein; and
contacting said plurality of cells with a second protein, wherein said second protein is a fusion protein comprised of a first domain having affinity for said first protein and a second domain of a peptide, protein, or derivative or fragment thereof, having a trans signaling or adhesion function specific for the treatment of the illness; and
administering an effective amount of said coated cells to a patient.
27. The method of claim 26 , wherein said illness is selected from the group consisting of cancer, autoimmune diseases, and alloimmune diseases.
28. The method of claim 27 , wherein said illness is cancer and said administration is by injection into a tumor.
29. The method of claim 26 , wherein said cells are autologous.
30. The method of claim 26 , wherein said cells are allogeneic.
31. The method of claim 30 , wherein said cells are an allogeneic cell line.
32. A method for treating a patient for an illness comprising:
transferring protein to a plurality of cells by administering to said patient a first protein, which is a lipidated protein;
and a second protein, which is a fusion protein comprised of a first domain having affinity for said first protein and a second domain of a peptide, protein, or derivative or fragment thereof, having a trans signaling or adhesion function specific for the treatment of the illness;
wherein an effective amount of cells within said patient have fusion protein transferred thereto.
33. The method of claim 32 , wherein said first protein and said second protein are administered sequentially.
34. The method of claim 32 wherein said first protein and said second protein are administered concurrently.
35. The method of claim 32 , wherein said administration is by local injection.
36. The method of claim 32 , wherein said administration is by systemic injection.
37. A cancer vaccine comprising:
cells produced according to the method of claim 1 in a suitable carrier.
38. The cancer vaccine of claim 37 , wherein said first protein is selected from the group consisting of lipidated protein A and lipidated protein G.
39. The cancer vaccine of claim 37 , wherein said first protein is palmitated protein A.
40. The cancer vaccine of claim 37 , wherein said first domain is attached at the amino terminus of said second protein.
41. The cancer vaccine of claim 37 , wherein said first domain is attached at the carboxyl terminus of said second protein.
42. The cancer vaccine of claim 37 , wherein said second domain encodes a type I membrane protein.
43. The cancer vaccine of claim 37 , wherein said second domain encodes a type II membrane protein.
44. The cancer vaccine of claim 37 , wherein said second domain encodes a costimulator.
45. The cancer vaccine of claim 37 , wherein said second domain encodes a coinhibitor.
46. The cancer vaccine of claim 44 , wherein said costimulator is selected from the group consisting of B7-1, B7-2, ICAM-1, ICAM-2, ICAM-3, CD48, LFA-3, 4-1BB ligand, CD30 ligand, CD40 ligand, and heat stable antigen.
47. The cancer vaccine of claim 46 , wherein said second protein is B7-1·Fcγ1.
48. The cancer vaccine of claim 45 , wherein said coinhibitor is selected from the group consisting of CD8, Fas ligand and a single chain Fv derivative of immunoglobulin.
49. The cancer vaccine of claim 37 , wherein said vaccine comprises more than one second protein.
50. The cancer vaccine of claim 37 , wherein said vaccine comprises more than one cell type, and each cell type has a different fusion protein transferred thereto.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/957,056 US20020037583A1 (en) | 2000-01-03 | 2001-09-20 | Methods for protein transfer |
US10/205,524 US7435585B2 (en) | 2000-01-03 | 2002-07-25 | Auto-stimulating cells and methods for making and using the same |
US10/775,942 US20040161806A1 (en) | 2000-01-03 | 2004-02-10 | Cells having transferred proteins, and methods of use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/476,828 US6316256B1 (en) | 2000-01-03 | 2000-01-03 | Method for protein transfer |
US09/957,056 US20020037583A1 (en) | 2000-01-03 | 2001-09-20 | Methods for protein transfer |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/476,828 Division US6316256B1 (en) | 2000-01-03 | 2000-01-03 | Method for protein transfer |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/205,524 Continuation-In-Part US7435585B2 (en) | 2000-01-03 | 2002-07-25 | Auto-stimulating cells and methods for making and using the same |
US10/775,942 Division US20040161806A1 (en) | 2000-01-03 | 2004-02-10 | Cells having transferred proteins, and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020037583A1 true US20020037583A1 (en) | 2002-03-28 |
Family
ID=23893419
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/476,828 Expired - Fee Related US6316256B1 (en) | 2000-01-03 | 2000-01-03 | Method for protein transfer |
US09/957,056 Abandoned US20020037583A1 (en) | 2000-01-03 | 2001-09-20 | Methods for protein transfer |
US10/775,942 Abandoned US20040161806A1 (en) | 2000-01-03 | 2004-02-10 | Cells having transferred proteins, and methods of use thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/476,828 Expired - Fee Related US6316256B1 (en) | 2000-01-03 | 2000-01-03 | Method for protein transfer |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/775,942 Abandoned US20040161806A1 (en) | 2000-01-03 | 2004-02-10 | Cells having transferred proteins, and methods of use thereof |
Country Status (7)
Country | Link |
---|---|
US (3) | US6316256B1 (en) |
EP (1) | EP1246901A4 (en) |
JP (1) | JP2003519240A (en) |
AU (1) | AU2472501A (en) |
CA (1) | CA2396399A1 (en) |
IL (2) | IL150570A0 (en) |
WO (1) | WO2001049825A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7435585B2 (en) * | 2000-01-03 | 2008-10-14 | University Of Pennsylvania | Auto-stimulating cells and methods for making and using the same |
IL161341A0 (en) * | 2001-10-16 | 2004-09-27 | Kiwi Ingenuity Ltd | Sensitivity controls for blood serology prepared from modified cells |
US7736657B2 (en) * | 2002-02-10 | 2010-06-15 | Apoxis S.A. | Fusion constructs containing active sections on TNF ligands |
WO2003106640A2 (en) * | 2002-06-14 | 2003-12-24 | Case Western Reserve University | Cell targeting methods and compositions |
US8580749B2 (en) * | 2009-06-05 | 2013-11-12 | Cell Targeting, Inc. | Peptide-coated cell localization to diseased or damaged tissues and methods related thereto |
EP2951209A4 (en) | 2013-01-31 | 2016-06-22 | Univ Jefferson | Agonist fusion protein for cd40 ox40 and uses thereof |
EP3277313B1 (en) * | 2015-04-02 | 2021-06-23 | Cancure Limited | Agents and compositions for eliciting an immune response |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5601828A (en) | 1989-03-15 | 1997-02-11 | Tkb Associates Limited Partnership | CD8 derivatives and methods of use for cellular modulation and enhancement of cellular engraftment |
AU5342290A (en) | 1989-03-15 | 1990-10-09 | David R. Kaplan | Cd8-based pharmaceuticals |
US5242687A (en) | 1989-03-15 | 1993-09-07 | Tkb Associates Limited Partnership | Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells |
US5698679A (en) | 1994-09-19 | 1997-12-16 | National Jewish Center For Immunology And Respiratory Medicine | Product and process for targeting an immune response |
US5817789A (en) | 1995-06-06 | 1998-10-06 | Transkaryotic Therapies, Inc. | Chimeric proteins for use in transport of a selected substance into cells |
US5869270A (en) * | 1996-01-31 | 1999-02-09 | Sunol Molecular Corporation | Single chain MHC complexes and uses thereof |
-
2000
- 2000-01-03 US US09/476,828 patent/US6316256B1/en not_active Expired - Fee Related
-
2001
- 2001-01-03 IL IL15057001A patent/IL150570A0/en active IP Right Grant
- 2001-01-03 WO PCT/US2001/000103 patent/WO2001049825A1/en active Application Filing
- 2001-01-03 EP EP01900311A patent/EP1246901A4/en not_active Ceased
- 2001-01-03 CA CA002396399A patent/CA2396399A1/en not_active Abandoned
- 2001-01-03 AU AU24725/01A patent/AU2472501A/en not_active Abandoned
- 2001-01-03 JP JP2001550354A patent/JP2003519240A/en active Pending
- 2001-09-20 US US09/957,056 patent/US20020037583A1/en not_active Abandoned
-
2002
- 2002-07-03 IL IL150570A patent/IL150570A/en not_active IP Right Cessation
-
2004
- 2004-02-10 US US10/775,942 patent/US20040161806A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20040161806A1 (en) | 2004-08-19 |
EP1246901A1 (en) | 2002-10-09 |
IL150570A0 (en) | 2003-02-12 |
CA2396399A1 (en) | 2001-07-12 |
AU2472501A (en) | 2001-07-16 |
EP1246901A4 (en) | 2004-11-03 |
IL150570A (en) | 2007-12-03 |
US6316256B1 (en) | 2001-11-13 |
WO2001049825A1 (en) | 2001-07-12 |
JP2003519240A (en) | 2003-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7435585B2 (en) | Auto-stimulating cells and methods for making and using the same | |
JP4741074B2 (en) | Composition comprising OX-40 receptor binding factor or nucleic acid encoding the same and method for enhancing antigen-specific immune response | |
Mackey et al. | The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells | |
Fallarino et al. | Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo | |
US7504101B2 (en) | Methods for enhancing antigen-specific immune response using antibodies that bind OX-40 | |
Clarke | The critical role of CD40/CD40L in the CD4-dependent generation of CD8+ T cell immunity | |
US11530251B2 (en) | Methods for cancer therapy using isolated NTB-A ectodomain polypeptides | |
AU2009226077B2 (en) | Heat shock protein gp96 vaccination and methods of using same | |
JP5557765B2 (en) | Use of soluble CD83 protein and nucleic acid encoding the same for treatment or prevention of diseases | |
US6316256B1 (en) | Method for protein transfer | |
IL166467A (en) | Methods of making and using auto-stimulating cells | |
MXPA00008176A (en) | Compositions containing an ox-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response | |
Mackey | The role of CD40/CD154 interactions in the generation of protective tumor immunity | |
EP1210420A1 (en) | Cd154 ligand, and recombinant cells expressing it |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: TYKOCINSKI, MARK L., PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TR ASSOCIATES, LLC;REEL/FRAME:017186/0574 Effective date: 20060213 |